Version 1
: Received: 2 June 2024 / Approved: 3 June 2024 / Online: 3 June 2024 (09:00:07 CEST)
How to cite:
Álvarez-Moreno, C. A.; Kock, J.; Cely, L.; Montañez Ayala, A.; Salcedo García, O.; Hernandez Quintana, M. A. The Effectiveness of Generic Piperacillin/Tazobactam in Managing Gram-Negative Bacillary Bacteremia in Adult Patients at a Tertiary Care Hospital. Preprints2024, 2024060045. https://doi.org/10.20944/preprints202406.0045.v1
Álvarez-Moreno, C. A.; Kock, J.; Cely, L.; Montañez Ayala, A.; Salcedo García, O.; Hernandez Quintana, M. A. The Effectiveness of Generic Piperacillin/Tazobactam in Managing Gram-Negative Bacillary Bacteremia in Adult Patients at a Tertiary Care Hospital. Preprints 2024, 2024060045. https://doi.org/10.20944/preprints202406.0045.v1
Álvarez-Moreno, C. A.; Kock, J.; Cely, L.; Montañez Ayala, A.; Salcedo García, O.; Hernandez Quintana, M. A. The Effectiveness of Generic Piperacillin/Tazobactam in Managing Gram-Negative Bacillary Bacteremia in Adult Patients at a Tertiary Care Hospital. Preprints2024, 2024060045. https://doi.org/10.20944/preprints202406.0045.v1
APA Style
Álvarez-Moreno, C. A., Kock, J., Cely, L., Montañez Ayala, A., Salcedo García, O., & Hernandez Quintana, M. A. (2024). The Effectiveness of Generic Piperacillin/Tazobactam in Managing Gram-Negative Bacillary Bacteremia in Adult Patients at a Tertiary Care Hospital. Preprints. https://doi.org/10.20944/preprints202406.0045.v1
Chicago/Turabian Style
Álvarez-Moreno, C. A., Oscar Salcedo García and Mauricio Andres Hernandez Quintana. 2024 "The Effectiveness of Generic Piperacillin/Tazobactam in Managing Gram-Negative Bacillary Bacteremia in Adult Patients at a Tertiary Care Hospital" Preprints. https://doi.org/10.20944/preprints202406.0045.v1
Abstract
Background: Gram-negative bacteremia, especially from Klebsiella spp., Escherichia coli, and Pseudomonas aeruginosa, poses a significant public health threat due to multidrug resistance and high mortality rates. Cost-effective treatments are essential in low-middle income countries as Colombia. Methods: This descriptive, phase IV study was conducted in a tertiary care hospital in Colombia. Adult patients with Gram-negative bacteremia treated with generic piperacillin/tazobactam (Penibactam®) were evaluated. Clinical and microbiological responses were assessed over 12 months. Results: The study included 30 critically ill patients with an average APACHE II score of 22.12. The clinical response at day 7 was 66% (n = 20), and the microbiological response was 56.7% (n = 17). By the end of follow-up, clinical improvement was observed in 63.3% (n = 19), with a mortality rate of 23% (n = 7). The cardiovascular system was the most common infection site. Conclusions: Generic piperacillin/tazobactam demonstrated effectiveness and safety comparable to existing literature in treating Gram-negative bacteremia, offering a viable, cost-effective alternative for critically ill patients in real-world settings.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
,
